Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Hoth Therapeutics, Inc. (HOTH : NSDQ)

• Company Description    Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is based in New York, United States. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $0.43 Daily Weekly Monthly 20 Day Moving Average: 837,658 shares Shares Outstanding: 32.21 (millions) Market Capitalization: $13.96 (millions) Beta: 1.11 52 Week High: $2.20 52 Week Low: $0.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -30.89% -22.17% 12 Week -23.98% -16.44% Year To Date -34.34% -20.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 Rockefeller Plaza Suite 1039 - New York,NY 10020 USA ph: 646-756-2997 fax: - investorrelations@hoththerapeutics.com http://www.hoththerapeutics.com

• General Corporate Information    Officers Robb Knie - Chief Executive Officer and President David Briones - Chief Financial Officer Wayne Linsley - Director David B. Sarnoff - Director Graig Springer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44148G105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/21 Next Expected EPS Date: 05/26/22 Share - Related Items Shares Outstanding: 32.21 Most Recent Split Date: (:1) Beta: 1.11 Market Capitalization: $13.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/26/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.77 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 12.50% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -105.89 12/31/21 - -95.82 09/30/21 - -85.05 ROA 03/31/22 - -95.01 12/31/21 - -87.82 09/30/21 - -77.99 Current Ratio 03/31/22 - 10.33 12/31/21 - 12.18 09/30/21 - 9.20 Quick Ratio 03/31/22 - - 12/31/21 - 12.18 09/30/21 - 9.20 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.24 12/31/21 - 0.41 09/30/21 - 0.56 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©